Kamiren

Doxazosin, the active ingredient in Kamiren, is an alpha‑1 adrenergic blocker presented as an oral tablet for oral use. It lowers high blood pressure and eases urinary symptoms associated with benign prostatic hyperplasia in adult patients.

GNH USA supplies Kamiren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to global markets.

Doxazosin is used to manage conditions that involve the alpha‑1 adrenergic pathway, primarily cardiovascular and urological disorders.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing urgency.

Doxazosin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Peripheral edema - Nausea

Serious or Rare Side Effects: - Severe hypotension - Syncope - Priapism - Hepatic dysfunction - Angioedema - Neutropenia

When prescribing Doxazosin, clinicians should consider several safety measures.

- Blood pressure monitoring: check baseline and periodic readings, especially after dose changes. - Orthostatic hypotension risk: advise patients to rise slowly from sitting or lying positions. - Renal impairment: assess renal function and adjust therapy if needed. - Drug interactions: review concomitant medications that affect blood pressure. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Doxazosin can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): may cause additive hypotensive effect. - Other alpha‑blockers (e.g., prazosin): risk of severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Non‑dihydropyridine calcium channel blockers (e.g., verapamil): may enhance hypotensive effect. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: may mask tachycardia that signals hypotension.